U.S.-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences have launched a new company armed with $180 million in series A funds and a clinical-stage CD38-targeting ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback